• Member News

Domainex appoints Dr Trevor Perrior as Chief Executive Officer

Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018.

Novel deep learning drug discovery platform gets £1 million innovation boost

Funding to support Artificial Intelligence (AI) in drug discovery takes a significant step forward today as Optibrium™, Intellegens, and Medicines Discovery Catapult secure a grant from Innovate UK to fund a £1 million project.

Evonetix makes key appointments to support development of novel gene synthesis technology

CAMBRIDGE, UK, 18 September 2018 – EVONETIX LTD (‘Evonetix’), the company pioneering an innovative approach to scalable and high-fidelity gene synthesis, announced today that it has expanded its team three-fold, following a successful series A round of £9 million ($12.3M) to support the development of the Company’s technology.

Stevenage Cell and Gene Therapy Catapult centre gets green light to make new cell and gene therapies

New life-changing cell and gene therapies for use in health services around the world will be produced in Stevenage by innovative biotech firms as the Cell and Gene Therapy Catapult (CGT Catapult) is granted new licences.

Accelerate@Babraham attracts additional support from Taylor Vinters and Silicon Valley Bank

International law firm and technology focused banking group confirm support for Accelerate@Babraham’s inaugural programme

Glythera Announces Corporate Name Change and Rebranding to Iksuda Therapeutics

Newcastle, UK, 10th September, 2018: Glythera Limited (Glythera), the next-generation Antibody Drug Conjugate (ADC) development company, today announced that it has changed its name to Iksuda Therapeutics (Iksuda) and unveiled a new corporate brand.


“Investment will accelerate the delivery of significantly improved therapeutic treatments and quality of life for people living with diabetes”

LifeArc announces new CEO appointment

LifeArc, one of the UK’s leading medical research charities, is delighted to announce the appointment of Melanie Lee, PhD, CBE as its new Chief Executive Officer (CEO), effective 1st November 2018.

Horizon Discovery announces collaboration with major pharmaceutical company on single cell RNAseq-linked CRISPR screening

Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company", or "the Group"), a global leader in gene editing and gene modulation technologies, today announces that is has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification and validation.

Blue Earth Diagnostics shortlisted for prestigious “Best Emerging Biotech Company” award

Oxford, UK – August 9, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, yesterday announced that it has been shortlisted as a finalist in the 2018 OBN awards in the category “Best Emerging Biotech Company”. These prestigious awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry.